New User:

Forgot your password?

Stock Market & Financial Investment News

News For PRXL;SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
07:31 EDTPRXLPAREXEL difficulties unlikely to be permanent, says Wells Fargo
Wells Fargo believes that the decline in PAREXEL's stock suggests that investors believe the company's strategic relationship are permanently impaired, while its book to bills will not recover to at least 1.1 in the near future. The firm does not know what is causing the reduction in the company's new business, but does not believe that the situation is permanent. Wells cut its valuation range on the name to $65-$68 from $70-$75 but says the weakness i nthe shares has created a buying opportunity.
October 30, 2014
10:02 EDTPRXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:04 EDTPRXLPAREXEL downgraded to Neutral from Outperform at RW Baird
Baird downgraded PAREXEL to Neutral following the Q1 report and disappointing guidance.
October 29, 2014
18:59 EDTPRXLOn The Fly: After Hours Movers
Subscribe for More Information
16:14 EDTPRXLPAREXEL sees FY15 EPS $2.56-$2.75, consensus $2.69
Subscribe for More Information
16:13 EDTPRXLPAREXEL sees Q2 EPS 56c-62c, consensus 66c
Sees Q2 revenue $495M-$508M, consensus $539.08M.
16:12 EDTPRXLPAREXEL reports Q1 adjusted EPS 65c, consensus 58c
Subscribe for More Information
October 27, 2014
05:38 EDTPRXLICON plc downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
October 21, 2014
06:06 EDTSGYPSynergy Pharm' presents positive data from phase 2b study of plecanatide
Synergy Pharmaceuticals announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients with irritable bowel syndrome with constipation. Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period. Notably, patients taking 3.0 and 9.0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use